Wilex elects to receive cash payment from Prometheus

Friday 6 July 2012

Wilex AG has elected to receive a final cash payment from Prometheus Laboratories Inc (Nestle SA) in connection with the out-licensing in 2011 of its cancer product Rencarex (girentuximab). The product is in a Phase 3 registration trial.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany